Lidoposterin

Lidocaine, the active ingredient in Lidoposterin, is a local anesthetic presented as a rectal formulation for rectal use. It provides topical analgesia for localized pain and is employed in certain anorectal procedures and conditions. GNH USA supplies Lidoposterin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidoposterin is a lidocaine‑based product that acts on peripheral nerves to provide local anesthesia in the rectal area. - Anorectal surgery: supplies localized anesthesia to reduce procedural pain. - Hemorrhoidal disease: relieves discomfort associated with hemorrhoids. - Proctitis: alleviates inflammation‑related pain in the rectal mucosa.

Lidoposterin may cause a range of adverse reactions, most of which are mild and related to local exposure.

Common Side Effects: - Local irritation or burning sensation at the application site. - Numbness extending beyond the intended area. - Mild dizziness or headache. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Allergic reactions such as rash, swelling, or anaphylaxis. - Methemoglobinemia, presenting as cyanosis or shortness of breath. - Central nervous system toxicity, including seizures or altered mental status.

Before using Lidoposterin, consider the following safety measures. - Assess allergy: verify that the patient has no known hypersensitivity to lidocaine or related amide anesthetics. - Monitor cardiac status: observe for arrhythmias in patients with pre‑existing heart disease. - Use with caution in hepatic impairment: lidocaine is metabolised by the liver and may accumulate. - Avoid excessive dose: adhere strictly to the prescriber's instructions. - Store at room temperature: keep in the original container, protect from moisture and light.

Lidoposterin can interact with other medicines, requiring attention to avoid toxicity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise plasma lidocaine levels. - Beta‑blockers: may potentiate cardiac depressant effects.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase local irritation. - Epinephrine: can alter lidocaine absorption and systemic exposure. - Concurrent use of other local anesthetics: additive toxicity risk.